Connect your AI

Alumis Inc. ALMS Accrued Progress Collections and Price Adjustments

Accrued Progress Collections and Price Adjustments at other companies

Kymera TherapeuticsKYMR

——

Adaptive BiotechnologiesADPT

——

Regeneron PharmaceuticalsREGN

——

Aurinia PharmaceuticalsAUPH

——

Other financials

Income statement

Revenue$1.7M-90.0%

Operating income-$98.4M+3.1%

Net income-$93.1M+6.0%

EPS (diluted)-$0.74+59.3%

Balance sheet

Cash & equivalents$63.9M-50.3%

Total debt$35.7M+1,881%

Total equity$567.0M+237%

Total assets$671.6M+157%

Cash flow

Operating cash flow-$87.1M-8.4%

CapEx$164.0K+343%

Free cash flow-$87.2M-8.5%

Valuation

Market cap$3.17B+739%

Profitability

Operating margin-5,364%—

Net margin-2,825.7%—

FCF margin-4,487.4%—

Returns & leverage

Return on equity-64.6%—

Debt / equity0.1×+0.1×

Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s accrued progress collections and price adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Alumis Inc.'s accrued progress collections and price adjustments?: Alumis Inc. (ALMS) reported accrued progress collections and price adjustments of $2.61M in Q4 2025.